Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Hodgkin’s Lymphoma – Geographic Focus: China – China In-Depth – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (…
Amyloidosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyloidosis is caused by the deposition of insoluble amyloid fibrils formed by the accumulation of misfolded proteins in affected organs. Amyloid immunoglobulin light chain (AL), amyloid A (AA),…
Ulcerative Colitis – Geographic Focus: China – Ulcerative Colitis – China In-Depth (China)
Ulcerative colitis (UC) is a chronic and progressive autoimmune disease that affects the gastrointestinal tract, specifically the colon and rectum. The principal goals of pharmacotherapy for UC are…
Non-Small-Cell Lung Cancer – Geographic Focus: China – Non-Small-Cell Lung Cancer – China In-Depth (China)
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in China. The treatment plan for NSCLC patients depends on their biomarker status; EGFR- and ALK-positive patients…
Myelodysplastic Syndromes | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2024
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenia and the risk of progression to acute myeloid leukemia (AML). Bristol…
Major Depressive Disorder (DSM-V) – Unmet Need – Unmet Need – Treatment-Resistant Depression (US/EU)
Major depressive disorder (MDD) is typically treated with psychotherapy, pharmacotherapy, or a combination of the two. The MDD therapy market is highly genericized; for patients experiencing…
Idiopathic Pulmonary Fibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…
